Skip to main content

Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer

Supportive Care in Cancer volume 28, pages 4687–4695 (2020)Cite this article

Abstract

Purpose

To evaluate adherence to abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Methods

In an observational prospective cohort study, we monitored patients with mCRPC for their adherence to abiraterone or enzalutamide in the pre- or post-chemotherapy setting.

Results

Fifty-eight patients with median age of 76 years (range 56–94), age-adjusted Charlson comorbidity score of 10 (range, 4–15), and geriatric G8 score of 14 (range, 6–17) were enrolled. Twenty-two (38%) patients were treated with abiraterone and 36 (62%) with enzalutamide, while forty-two (72%) were in the pre-chemotherapy setting. Forty-seven patients (81%) had a caregiver. Based on the pill counting, a non-adherence rate of 4.8% and 6.2% was observed for the whole period and the first 3 months, respectively, without a statistically significant difference between abiraterone and enzalutamide cohorts. A lower non-adherence rate (1.3%) was reported by patients during the whole period, mainly due to a misperception (77%) and forgetfulness (19%). Non-adherence rate to the fulfilling of the clinical diary was 38% for the whole period. Non-adherence in the whole period was related to the radiological response (p = 0.03) and geriatric G8 score (p = 0.005). By the receiver operating characteristic (ROC) curve based on the radiological response, non-adherence cut-off was 1.87% (p = 0.04). By this non-adherence cut-off, the G8 cut-off was 14.75 (p = 0.0003).

Conclusion

Non-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients’ frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS (2019) Managing nonmetastatic castration-resistant prostate cancer. Eur Urol 75(2):285–293. https://doi.org/10.1016/j.eururo.2018.07.035

    Article  PubMed  Google Scholar 

  2. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 75(1):88–99. https://doi.org/10.1016/j.eururo.2018.03.028

    Article  PubMed  Google Scholar 

  3. Banna GL, Collova E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferrau F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36(8):595–605. https://doi.org/10.1016/j.ctrv.2010.04.005

    Article  PubMed  Google Scholar 

  4. Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, Pirl WF, Temel JS, Greer JA (2017) Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract 13(5):e474–e485. https://doi.org/10.1200/JOP.2016.019729

    Article  PubMed  Google Scholar 

  5. Gebbia V, Bellavia M, Banna GL, Russo P, Ferrau F, Tralongo P, Borsellino N (2013) Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clinical lung cancer 14(4):390–398. https://doi.org/10.1016/j.cllc.2012.11.007

    Article  CAS  PubMed  Google Scholar 

  6. Nguyen TM, La Caze A, Cottrell N (2014) What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol 77(3):427–445. https://doi.org/10.1111/bcp.12194

    Article  PubMed  PubMed Central  Google Scholar 

  7. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342(8878):1032–1036. https://doi.org/10.1016/0140-6736(93)92884-v

    Article  CAS  PubMed  Google Scholar 

  8. Devons CA (2002) Comprehensive geriatric assessment: making the most of the aging years. Curr Opin Clin Nutr Metab Care 5(1):19–24

    Article  Google Scholar 

  9. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

    Article  CAS  Google Scholar 

  10. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251

    Article  CAS  Google Scholar 

  11. Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safren SA, Pirl WF (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):354–376. https://doi.org/10.1634/theoncologist.2015-0405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cleemput I, Dobbels F (2007) Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date. PharmacoEconomics 25(4):269–286. https://doi.org/10.2165/00019053-200725040-00002

    Article  PubMed  Google Scholar 

  13. Wilcoxon F (1945) Individual comparisons by ranking methods. Biom Bull 1(6):80–83. https://doi.org/10.2307/3001968

    Article  Google Scholar 

  14. Fisher RA (1922) On the interpretation of χ<sup>2</sup> from contingency tables, and the calculation of P. J R Stat Soc 85(1):87–94. https://doi.org/10.2307/2340521

    Article  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  Google Scholar 

  16. Kaplan EL, Meier P (1958) Nonparamentric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481

    Article  Google Scholar 

  17. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50(3):163–170

    CAS  PubMed  Google Scholar 

  18. Fieller EC, Hartley HO, Pearson ES (1957) Tests for rank correlation coefficients. I Biometrika 44(3–4):470–481. https://doi.org/10.1093/biomet/44.3-4.470

    Article  Google Scholar 

  19. Fawcett T (2006) An introduction to ROC analysis. Pattern Recogn Lett 27(8):861–874. https://doi.org/10.1016/j.patrec.2005.10.010

    Article  Google Scholar 

  20. Unni EJ, Farris KB (2011) Unintentional non-adherence and belief in medicines in older adults. Patient Educ Couns 83(2):265–268. https://doi.org/10.1016/j.pec.2010.05.006

    Article  PubMed  Google Scholar 

  21. Schneider SM, Hess K, Gosselin T (2011) Interventions to promote adherence with oral agents. Semin Oncol Nurs 27(2):133–141. https://doi.org/10.1016/j.soncn.2011.02.005

    Article  PubMed  PubMed Central  Google Scholar 

  22. Bruijnen CP, van Harten-Krouwel DG, Koldenhof JJ, Emmelot-Vonk MH, Witteveen PO Predictive value of each geriatric assessment domain for older patients with cancer: a systematic review. J Geriatr Oncolo. https://doi.org/10.1016/j.jgo.2019.02.010

  23. Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. JNCI: Journal of the National Cancer Institute 94(9):652–661. https://doi.org/10.1093/jnci/94.9.652

    Article  PubMed  Google Scholar 

  24. Gornas M, Szczylik C (2010) Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process? Eur J Cancer Care (Engl) 19(1):131–136. https://doi.org/10.1111/j.1365-2354.2008.00999.x

    Article  CAS  Google Scholar 

  25. Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, Coolbrandt A, Biganzoli L (2017) Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev 57:58–66. https://doi.org/10.1016/j.ctrv.2017.05.002

    Article  PubMed  Google Scholar 

  26. Glajchen M (2004) The emerging role and needs of family caregivers in cancer care. J Support Oncol 2(2):145–155

    PubMed  Google Scholar 

  27. O'Quin KE, Semalulu T, Orom H (2015) Elder and caregiver solutions to improve medication adherence. Health Educ Res 30(2):323–335. https://doi.org/10.1093/her/cyv009

    Article  CAS  PubMed  Google Scholar 

  28. Costa E, Giardini A, Savin M, Menditto E, Lehane E, Laosa O, Pecorelli S, Monaco A, Marengoni A (2015) Interventional tools to improve medication adherence: review of literature. Patient Prefer Adherence 9:1303–1314. https://doi.org/10.2147/PPA.S87551

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy

    Giuseppe L. Banna, Chiara Benanti, Alessandra Pitrè & Helga Lipari

  2. Department of Medical Oncology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK

    Giuseppe L. Banna

  3. Department of Clinical and Experimental Medicine, Cannizzaro Hospital, University of Catania, Catania, Italy

    Valeria Urzia, Rosario Di Quattro & Lorenzo Malatino

  4. Department of Medical Oncology, Istituto Scientifico Romagnolo per Io Studio e La Cura dei Tumori (IRST) IRCCS, Meldola, Italy

    Ugo De Giorgi & Giuseppe Schepisi

  5. Medical Oncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy

    Umberto Basso & Davide Bimbatti

  6. STMicroelectronics ADG Central R&D, Catania, Italy

    Francesco Rundo

  7. Department of Biomedical and Biotechnological Sciences, Pathology and Oncology Section, University of Catania, Catania, Italy

    Massimo Libra

Authors
  1. Giuseppe L. Banna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valeria Urzia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Benanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandra Pitrè
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Helga Lipari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rosario Di Quattro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ugo De Giorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giuseppe Schepisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Umberto Basso
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Davide Bimbatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Francesco Rundo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Massimo Libra
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Lorenzo Malatino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe L. Banna.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Banna, G.L., Urzia, V., Benanti, C. et al. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Support Care Cancer 28, 4687–4695 (2020). https://doi.org/10.1007/s00520-020-05311-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05311-5

Keywords

  • Adherence
  • Compliance
  • Prostate cancer
  • Abiraterone
  • Enzalutamide
  • Elderly